Content area

|
|

Immunterapi med checkpointhæmmere og endokrinologiske bivirkninger

Forfattere
Line Bisgaard Jørgensen1, Lars Bastholt2 & Knud Yderstræde1 1) Endokrinologisk Afdeling, Odense Universitetshospital 2) Onkologisk Afdeling, Odense Universitets-hospital Ugeskr Læger 2017;179:V05170362
Reference: 
Ugeskr Læger 2017;179:V05170362
Blad nummer: 
Sidetal: 
2-6
Immune checkpoint inhibitors and endocrinological side effects
Immune checkpoint inhibitors including anti-cytotoxic T-lymphocyte-associated antigen-4 and anti-programmed cell death-1 have revolutionized cancer therapy but have also induced serious immune-related adverse events including hormonal dysfunction. The objective of this review is to characterize the incidence, clinical presentation, management and prognosis of the endocrine-related adverse events including hypophysitis, thyroid dysfunction and diabetes mellitus. Combination therapy is associated with an increased risk of adverse events. We recommend close monitoring of the hormone levels and glycaemic status during and a year after treatment.

💬 0 Kommentarer

Du skal være logget ind for at læse denne artikel
Log ind

Right side

af Lars Borly | 22/04
1 Kommentar
af Hanne Hulgaard | 22/04
1 Kommentar
af Per Kristian Kruhøffer | 21/04
1 Kommentar
af Kristian Rørbæk Madsen | 21/04
6 kommentarer
af Alice Kunkel | 21/04
1 Kommentar
af Klaus Larsen | 18/04
2 kommentarer
af Elo Aagaard Rasmussen | 17/04
5 kommentarer
af Jan Peter Baark | 15/04
3 kommentarer
af Mogens Stubkjær Hüttel | 15/04
2 kommentarer